RxDoctor Payments Data

Justin Snipes

Nurse Practitioner · Morganton, NCNPI 1275799967

Payments from drug & device makers

$8,716in general payments, 2019–2025

Across 518 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Lilly USA, LLC$992
  • AbbVie$936
  • Novo Nordisk$916
  • Otsuka America Pharmaceutical, Inc.$330
  • AstraZeneca$322
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$8,40896%
  • Education$3084%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,716 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$43,419
Medicare patients
97
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide120$140,757
Invega SustennaPaliperidone Palmitate45$134,292
JardianceEmpagliflozin119$118,482
EliquisApixaban145$97,250
OzempicSemaglutide90$96,394
RexultiBrexpiprazole66$92,561
IngrezzaValbenazine Tosylate11$87,071
Tresiba Flextouch U-100Insulin Degludec123$78,768
JanuviaSitagliptin Phosphate102$78,597
TrulicityDulaglutide65$74,305
MyrbetriqMirabegron97$60,592
ZenpepLipase/Protease/Amylase17$54,854
XareltoRivaroxaban86$54,835
FanaptIloperidone15$52,172
LinzessLinaclotide64$39,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$992$215,063185 claims
Johnson & JohnsonInvega Sustenna, Xarelto$204$189,126131 claims
Boehringer IngelheimJardiance, Spiriva Respimat$179$134,559148 claims
PfizerEliquis, Nurtec Odt$139$123,216162 claims
AbbVieLinzess, Vraylar, Ubrelvy, Namzaric$936$110,659124 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$322$99,148217 claims
Novo NordiskOzempic$916$96,39490 claims
MerckJanuvia, Lagevrio (Eua)$97$95,275120 claims
Otsuka America Pharmaceutical, Inc.Rexulti$330$92,56166 claims
Neurocrine Biosciences, Inc.Ingrezza$28$87,07111 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta$318$62,717122 claims
Astellas Pharma US IncMyrbetriq$194$60,59297 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Morganton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →